| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
IDH-305 manufacturers
- IDH-305
-
- $31.00
-
2026-07-13
- CAS:1628805-46-8
- Purity: 99.68%
- Supply Ability: 10g
|
| | IDH-305 Basic information |
| Product Name: | IDH-305 | | Synonyms: | IDH-305;(4R)-4-[(1S)-1-fluoroethyl]-3-(2-{[(1S)-1-[4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl]ethyl]amino}pyrimidin-4-yl)-1,3-oxazolidin-2-one;IDH-305;IDH 305;IDH305;2-Oxazolidinone, 4-[(1S)-1-fluoroethyl]-3-[2-[[(1S)-1-[4-methyl-2'-(trifluoromethyl)[3,4'-bipyridin]-6-yl]ethyl]amino]-4-pyrimidinyl]-, (4R)-;(4R)-4-[(1S)-1-Fluoroethyl]-3-[2-[[(1S)-1-[4-methyl-2'-(trifluoromethyl)[3,4'-bipyridin]-6-yl]ethyl]amino]-4-pyrimidinyl]-2-oxazolidinone;Isocitrate Dehydrogenase (IDH),IDH-305,Inhibitor,IDH305,inhibit,IDH 305;(R)-4-((S)-1-Fluoroethyl)-3-(2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;IDH-305, 10 mM in DMSO | | CAS: | 1628805-46-8 | | MF: | C23H22F4N6O2 | | MW: | 490.45 | | EINECS: | | | Product Categories: | | | Mol File: | 1628805-46-8.mol |  |
| | IDH-305 Chemical Properties |
| Boiling point | 597.6±60.0 °C(Predicted) | | density | 1.370±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 30 mg/ml; DMSO: 30 mg/ml; Ethanol: 30 mg/ml; Ethanol:PBS (pH7.2)(1:20): 0.05 mg/ml | | form | A crystalline solid | | pka | 4.07±0.10(Predicted) | | color | White to off-white |
| | IDH-305 Usage And Synthesis |
| Uses | (4R)-4-[(1S)-1-Fluoroethyl]-3-[2-[[(1S)-1-[4-methyl-2''-(trifluoromethyl)[3,4''-bipyridin]-6-yl]ethyl]amino]-4-pyrimidinyl]-2-oxazolidinone, is an inhibitor of isocitrate dehydrogenase (IDH) which is an essential enzyme for cellular respiration in the tricarboxylic acid (TCA) cycle. | | in vivo | IDH-305 (30-300 mg/kg; p.o.; twice daily for 21 days) inhibits 2-HG production and 2-HG-dependent tumor growth of an IDH1 mutant PDX melanoma model[1]. | Animal Model: | nu/nu mice (HMEX2838-IDH1R132C+/-PDX model)[1] | | Dosage: | 30, 100, 300 mg/kg | | Administration: | Oral gavage; twice daily for 21 days | | Result: | Resulted in 62-67% 2-HG reduction and significant anti-tumor activity at 100 mg/kg and 97-99% 2-HG reduction and partial tumor regression of 32% at 300 mg/kg. |
| | IC 50 | IDH1 |
| | IDH-305 Preparation Products And Raw materials |
|